Welcome to our dedicated page for Genprex news (Ticker: GNPX), a resource for investors and traders seeking the latest updates and insights on Genprex stock.
Genprex, Inc. (NASDAQ: GNPX) generates a steady flow of news as a clinical-stage gene therapy company developing treatments for cancer and diabetes. Its updates frequently center on progress in lung cancer trials with Reqorsa Gene Therapy (quaratusugene ozeplasmid) and preclinical advances in its diabetes program, GPX-002.
Investors following GNPX news can expect coverage of clinical trial milestones, such as dose-escalation results, Phase 2 expansion plans, new trial site additions, and peer-reviewed publications from studies like the Acclaim-1 and Acclaim-3 trials in non-small cell and small cell lung cancer. Company releases also highlight regulatory designations, including FDA Fast Track and Orphan Drug status for Reqorsa-based programs.
Another major news theme is preclinical and translational data. Genprex and its collaborators report findings on Reqorsa’s activity in specific lung cancer subtypes, including ALK-EML4-positive NSCLC models, as well as animal data showing TUSC2 upregulation, apoptosis induction, and survival benefits in xenograft studies. For diabetes, news often covers GPX-002 proof-of-concept data in Type 1 and Type 2 diabetes mouse and non-human primate models, including effects on beta-cell function and glucose control.
Genprex also issues corporate and regulatory announcements, such as registered direct offerings, at-the-market programs, warrant-related financings, and patent developments around Reqorsa combinations with PD-1 and PD-L1 antibodies. These items provide context on the company’s capital strategy and intellectual property position.
For readers tracking GNPX, this news stream offers insight into how Genprex’s gene therapy platforms are advancing through research, clinical development, regulatory interactions, and financing activities over time.
Genprex, Inc. (NASDAQ: GNPX) has been awarded the inaugural "License of the Year" from the University of Pittsburgh Innovation Institute for its diabetes gene therapy, GPX-002. This therapy aims to convert pancreas alpha cells into insulin-producing beta-like cells, potentially curing diabetes. Preclinical results show promise with mice, indicating blood glucose levels normalized for up to four months. The award recognizes the innovative work of Dr. George Gittes at UPMC, enhancing the company's reputation in gene therapy.
Genprex, Inc. (GNPX) announced promising preclinical data for its TUSC2 immunogene therapy (REQORSA™) presented at the AACR 2021 meeting. The data indicate that REQORSA, combined with chemotherapy and immunotherapies, enhances treatment efficacy for non-small cell lung cancer (NSCLC), particularly in cases resistant to existing therapies. Upcoming Acclaim-1 and Acclaim-2 clinical trials aim to explore these combinations further. The research highlights REQORSA's potential to address unmet needs in NSCLC treatment.
Genprex, Inc. (NASDAQ: GNPX) announces that Michael Redman, its Executive VP and COO, will present at the 2021 Virtual Cell & Gene Meeting on the Mediterranean from April 6-9, 2021. This event will feature over 80 company presentations and more than 50 expert panel discussions focusing on advancements in cell and gene therapy. Genprex aims to develop innovative therapies for cancer and diabetes, with its lead product candidate, REQORSA™, currently evaluated for non-small cell lung cancer. Registration is available for credentialed investors and media.
Genprex has announced that preclinical data on TUSC2 immunogene therapy (REQORSA™) will be presented at the AACR 21 meeting from April 9-14, 2021. This therapy aims to improve treatment outcomes for non-small cell lung cancer (NSCLC) by enhancing the efficacy of chemotherapy and overcoming resistance to osimertinib. The upcoming Acclaim-1 and Acclaim-2 clinical trials will evaluate REQORSA in combination with AstraZeneca’s Tagrisso® and Merck's Keytruda®. The presentations are expected to attract attention from leading cancer researchers.
Genprex, Inc. (NASDAQ: GNPX), a clinical-stage gene therapy company, will present at the Spring 2021 Oncology Investor Conference from March 29 to April 2, 2021. President and CEO Rodney Varner will deliver a virtual company overview on March 29 at 2 p.m. EDT, focusing on innovative gene therapies for non-small cell lung cancer and diabetes. Genprex's lead candidate, REQORSA™, has received Fast Track Designation by the FDA for treating NSCLC in combination with osimertinib, aiming to improve treatment options for patients with limited alternatives.
Genprex, Inc. (NASDAQ: GNPX), a clinical-stage gene therapy company, announced its participation in two investor conferences in March 2021. The events are the Sachs 14th Annual European Life Sciences CEO Forum, taking place from March 10-12, and the 33rd Annual Roth Conference from March 15-17. Presentations will be led by CEO Rodney Varner, with availability for one-on-one meetings with investors. The presentations will be available for replay on the company's website following the events.
Genprex, Inc. (NASDAQ: GNPX) has announced a registered direct offering of 4,000,000 shares of common stock at $6.25 per share to institutional investors. The offering, priced at-the-market under Nasdaq rules, is expected to close on or around February 11, 2021, pending customary conditions. A.G.P./Alliance Global Partners is acting as the sole placement agent for this deal. No warrants will be issued. The company aims to utilize the funds to advance its clinical-stage gene therapy programs, specifically targeting cancers and diabetes.
Genprex, a clinical-stage gene therapy company focused on cancer and diabetes, has established a Clinical Advisory Board (CAB) to support its oncology and diabetes programs. This board is composed of leading clinical specialists who will guide the development of Genprex’s REQORSA™ immunogene therapy for non-small cell lung cancer and its diabetes gene therapy. CEO Rodney Varner emphasized the importance of the CAB's expertise in advancing clinical trials. Notable members include Dr. Michael Morse from Duke University and Dr. George E. Peoples, a veteran in cancer vaccine development.
Genprex, Inc. (NASDAQ: GNPX) supports World Cancer Day to raise global cancer awareness and promote equity in healthcare. CEO Rodney Varner emphasized the company's dedication to innovative oncology treatments for patients with limited options. Genprex's lead candidate, REQORSA™, possesses FDA Fast Track Designation for non-small cell lung cancer (NSCLC) treatment in combination with AstraZeneca's Tagrisso®. Upcoming Acclaim-1 and Acclaim-2 trials are set to begin in the first half of 2021, focusing on NSCLC therapies.
Genprex, Inc. (NASDAQ: GNPX) announced a corporate update detailing its progress and plans for 2021. The company is set to initiate two pivotal clinical trials for its gene therapy candidate, REQORSA™, targeting non-small cell lung cancer (NSCLC). The Acclaim-1 trial will combine REQORSA with Tagrisso® for patients whose disease progressed after Tagrisso treatment, while Acclaim-2 will combine it with Keytruda® for low PD-L1 expressors. Genprex also highlighted $40 million in capital raised in 2020, strengthening its financial position.
FAQ
What is the current stock price of Genprex (GNPX)?
What is the market cap of Genprex (GNPX)?
